New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q) JOURNAL OF HEMATOLOGY & ONCOLOGY Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mittelman, M., Muus, P., Nimer, S. D., Hellstrom-Lindberg, E., Powell, B. L., Guerci-Bresler, A., Sekeres, M. A., Deeg, H., del Canizo, C., Greenberg, P. L., Shammo, J. M., Skikne, B., Yu, X., List, A. F. 2017; 10: 131Abstract
Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed.We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials.A total of 33.9, 34.3, and 31.8% patients were aged <65 years, =65 to <75 years, and =75 years, respectively. Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p?=?0.022 vs. =65 to <75 years; p?=?0.047 vs. =75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p?=?0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence =26 weeks.Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide.ClinicalTrials.gov NCT00065156 and NCT00179621.
View details for DOI 10.1186/s13045-017-0491-2
View details for Web of Science ID 000404058800001
View details for PubMedID 28651604
View details for PubMedCentralID PMC5485496